Search clinical trials for: Active JNJ Drug

Total 258180 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers

Healthy | Pharmacokinetics
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Czechia, Israel, Italy, Korea, Republic of, Brazil, United Kingdom, Japan, Taiwan, Australia, Poland, Spain, France, Russian Federation, Sweden, Ukraine, Greece
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
Janssen Research & Development, LLC

Completed

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease (TRIDENT)

Crohn Disease

United States, France, Poland, Ukraine, Germany, Belgium, Bulgaria, Romania, Japan, Canada, Korea, Republic of, Russian Federation, Hungary, United Kingdom
Janssen Research & Development, LLC
Genentech, Inc.

Completed

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)

Carcinoma, Non-Small-Cell Lung

France, United States, Spain, Hungary, Poland
Janssen Research & Development, LLC

Completed

Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Insomnia Disorders

Belgium, United States, Germany, Poland, Japan, France
Janssen Research & Development, LLC

Terminated

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Rheumatoid Arthritis

Poland, Ukraine, Taiwan, United States, Colombia, Mexico, Japan, Korea, Republic of, Russian Federation, Argentina, Chile, Thailand, Hungary, Romania, Czechia, Latvia
Janssen Research & Development, LLC

Active, not recruiting

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Depressive Disorder, Major

United States, Spain, Italy, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

Healthy

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Healthy | Hepatic Impairment

Germany
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
Actelion

Terminated

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment (SELECT)

Chronic Thromboembolic Pulmonary Hypertension

United States, Taiwan, Belgium, Canada, Korea, Republic of, United Kingdom, Turkey, Poland, Austria, Portugal, Spain, Italy, Switzerland, China, Malaysia, Netherlands, Australia, Thailand, Hungary, Brazil, Bulgaria, Czechia, Germany, ... and more
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

United States, Belgium, Canada, Hungary, Japan, Poland
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus (STEP)

Metapneumovirus

Netherlands, United States, France, Taiwan, Korea, Republic of, Australia, Japan, Spain, Malaysia, Russian Federation, Sweden, Poland, Bulgaria, Argentina, Brazil, Ukraine
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Healthy | Renal Impairment

United States
Janssen Research & Development, LLC

Completed

Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers

Healthy

United States
Actelion

Terminated

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag (SPHINX)

Sarcoidosis-associated Pulmonary Hypertension

United States, Germany, Canada, United Kingdom, Belgium, France, Netherlands, Italy, Brazil, Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (FRONTIER 1)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Canada, Japan, Taiwan, Spain, United Kingdom, Poland
Janssen Sciences Ireland UC

Completed

A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

Hepatitis B, Chronic

Belgium, Germany, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Terminated

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

Schizophrenia | Cognition Disorders | Alzheimer's Disease

Germany
Janssen Research & Development, LLC
The Scripps Research Institute

Withdrawn

Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

Alcoholism

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.

Healthy
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Janssen Sciences Ireland UC

Completed

A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

Healthy | Hepatitis, Chronic

France, Taiwan, Spain, Belgium, Bulgaria, Malaysia, Romania, Germany, Georgia, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Belgium, United States, Italy, Poland, Brazil, Denmark, Germany, Hungary, Mexico, Portugal, Russian Federation, Spain, Sweden, Turkey, Czechia, Finland, Austria, Australia, Lebanon, Slovakia, Jordan
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

Renal Insufficiency

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

United States, Israel
Janssen Research & Development, LLC

Recruiting

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)

Carcinoma, Non-Small-Cell Lung

Taiwan, United States, Korea, Republic of, Germany, France, China, Japan, Italy, Spain, Puerto Rico
Furiex Pharmaceuticals, Inc

Terminated

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia (CABP)

United States, Canada, Colombia, Germany, Hungary, Poland
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Janssen Pharmaceutical K.K.

Terminated

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Stomach Neoplasms | Esophageal Neoplasms

Japan
Janssen Research & Development, LLC

Completed

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome

United States, Germany, Netherlands, Japan, Taiwan, Italy, France, Spain, Poland, Portugal
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome

United States
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome

United States, Canada, Puerto Rico, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers

Healthy
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)

Leukemia, Myeloid, Acute

Switzerland, Israel, Spain, France, Turkey, Italy, Australia, Brazil, Russian Federation
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A Virus

United States, France, Belgium, Germany, Hong Kong, Spain, Malaysia, Turkey, Canada, Netherlands, Singapore, Brazil, New Zealand, Australia, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Adenocarcinoma | Prostatic Neoplasms

United States
Actelion

Active, not recruiting

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Belgium, Taiwan, Israel, United States, France, China, United Kingdom, Malaysia, Belarus, Canada, Germany, Hungary, Russian Federation, Serbia, Ukraine, Poland
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Multiple Myeloma

Japan

Search clinical trials for: Active JNJ Drug

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations